Neurocrine Biosciences Inc
NASDAQ:NBIX
Intrinsic Value
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. [ Read More ]
The intrinsic value of one
NBIX
stock under the Base Case scenario is
121.59
USD.
Compared to the current market price of 132.54 USD,
Neurocrine Biosciences Inc
is
Overvalued by 8%.
Neurocrine Biosciences Inc's market capitalization is 13.1B USD.
NBIX stock price is 132.54 USD.
NBIX stock (121.59 USD) is 8% less than its price (132.54 USD).
NBIX stock (119.78 USD) is 10% less than its price (132.54 USD). Open DCF Valuation
NBIX stock (123.4 USD) is 7% less than its price (132.54 USD). Open Relative Valuation
NBIX has upside potential of 17% compared to the average analyst price target.
Open Wall St Estimates
NBIX's ROE (Return on Equity) for the past 12 months is positive and is equal to 13%.
NBIX has positive Net Income for the last twelve months.
NBIX's Revenue has grown by an exceptional 27% over the past 12 months.
NBIX has positive Operating Income for the last twelve months.
NBIX's Revenue is forecast to grow at a rate of 16% per year over the next 3 years.
NBIX's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 28%.
NBIX has positive three-year average ROE (Return on Equity): 18%. The company is efficient at transforming stockholders' equity into net income.
NBIX's Revenue has been growing by an exceptional 22% per year for the last 3 years.
NBIX's ROE (Return on Equity) has significantly decreased in the last 3 years from 42% to 13%.
NBIX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 78% to 28%.
NBIX has positive Free Cash Flow for the last twelve months.
NBIX's short-term assets (2B USD) exceed its short-term liabilties (655m USD).
NBIX has positive Gross Profit for the last twelve months.
NBIX's long-term assets (3B USD) exceed its long-term liabilties (1B USD).
NBIX has very high three-year average ROIC (Return on Invested Capital): 55%. The company is very efficient at using invested capital to generate operating income.
NBIX's D/E (Debt to Equity) is very low and is equal to 0.
NBIX's Altman Z-Score is very high and is equal to 8.25.
NBIX earns more than enough operating income (395m USD) to safely cover interest payments on its debt (4m USD).
Valuation Backtest
Neurocrine Biosciences Inc
Run backtest to discover the historical profit from buying and selling
NBIX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Neurocrine Biosciences Inc
Balance Sheet Decomposition
Neurocrine Biosciences Inc
| Current Assets | 1.6B |
| Cash & Short-Term Investments | 1.8B |
| Receivables | 439.3m |
| Other Current Assets | -644.4m |
| Non-Current Assets | 1.6B |
| Long-Term Investments | 849.4m |
| PP&E | 347.3m |
| Intangibles | 35.5m |
| Other Non-Current Assets | 412.2m |
| Current Liabilities | 654.8m |
| Accounts Payable | 318.3m |
| Accrued Liabilities | 162.5m |
| Other Current Liabilities | 174m |
| Non-Current Liabilities | 364.6m |
| Other Non-Current Liabilities | 364.6m |
Earnings Waterfall
Neurocrine Biosciences Inc
|
Revenue
|
1.9B
USD
|
|
Cost of Revenue
|
-39.7m
USD
|
|
Gross Profit
|
1.8B
USD
|
|
Operating Expenses
|
-1.5B
USD
|
|
Operating Income
|
394.8m
USD
|
|
Other Expenses
|
-145.1m
USD
|
|
Net Income
|
249.7m
USD
|
Free Cash Flow Analysis
Neurocrine Biosciences Inc
What is Free Cash Flow?
NBIX Profitability Score
Profitability Due Diligence
Neurocrine Biosciences Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Neurocrine Biosciences Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
NBIX Solvency Score
Solvency Due Diligence
Neurocrine Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Neurocrine Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NBIX Price Targets Summary
Neurocrine Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
NBIX
is 155 USD
with a low forecast of 107.06 USD and a high forecast of 210 USD.
Ownership
NBIX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
NBIX Price
Neurocrine Biosciences Inc
| Average Annual Return | 12.94% |
| Standard Deviation of Annual Returns | 26.08% |
| Max Drawdown | -10% |
| Market Capitalization | 13.1B USD |
| Shares Outstanding | 102 300 000 |
| Percentage of Shares Shorted | 2.83% |
NBIX News
Last Important Events
Neurocrine Biosciences Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Neurocrine Biosciences Inc
Company Profile
Neurocrine Biosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 900 full-time employees. The firm is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Contact
IPO
Employees
Officers
The intrinsic value of one
NBIX
stock under the Base Case scenario is
121.59
USD.
Compared to the current market price of 132.54 USD,
Neurocrine Biosciences Inc
is
Overvalued by 8%.
You don't have any saved screeners yet
